BBC Sounds, Music, radio, podcasts.

Hello and welcome to your radical questions, where I put your questions to one of our radical guests.

This is your chance to engage directly

with the brilliant minds that we have on this podcast and ask them about their ideas for the future.

My name's John Byrne Murdoch, standing in for a mole this week. I'm a columnist and chief data reporter

for the Financial Times. I've just finished up a brilliant conversation with Sir John Bell,

who is Emeritus Regis Professor

of Medicine at Oxford University. And if you haven't heard that conversation yet, I'd encourage

you to go and listen. Professor Sir John has advised the UK government on life sciences,

pharmaceutical strategy and COVID testing and played a pivotal role in the development of the

AstraZeneca COVID-19 vaccine during the pandemic.

He's currently a partner at Population Health Partners, a firm focused on investing in and advising life science companies,

and he previously served on the board of pharmaceutical company Roche.

And he joins me now. Welcome back, Professor Sir John Bell.

Yeah, it's a pleasure to be here.

Well, we've got a really interesting question to start off with,

which I think gets into the nitty-gritty of some of this stuff.

So when we're talking about personalised medicine,

the listener Roxandra asks,

one of the big questions for her is how do these truly personalised therapies

fit alongside our current regulatory framework around clinical trials.

So she's spoken in her work in this space. She's spoken to very wealthy people who have the

...